The Association for Clinical Oncology (ASCO) submitted comments in response to a Centers for Medicare & Medicaid Services' (CMS) proposal is to streamline prior authorization by requiring Medicare Advantage plans, Medicaid plans, and Qualified Health Plans (QHP) on Federally Facilitated Exchanges (FFEs) to establish an electronic prior authorization process that would be integrated into a provider’s workflow.

The American Society of Clinical Oncology (ASCO) is working with eight oncology health systems to develop, test, and measure strategies to improve immunization rates as part of an initiative with the Council of Medical Specialty Societies (CMSS) to improve vaccination rates among high-risk adults.

The Association for Clinical Oncology (ASCO) submitted comments in response to the Centers for Medicare & Medicaid Services (CMS) Contract Year 2024 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit Programs proposed rule. ASCO’s comments focus heavily on the proposed changes to prior authorization in the MA program in addition to enhancing health equity and other updates to the Part D drug benefit program.

In anticipation of President Biden’s State of the Union Address, the Association for Clinical Oncology (ASCO) is urging the president to keep cancer care and research as top national priorities.

The Association for Clinical Oncology (ASCO) submitted comments in response to the Centers for Medicare & Medicaid Services’ (CMS) Patient Protection and Affordable Care Act 2024 Notice of Benefit and Payment Parameters proposed rule. ASCO’s comments support proposals aimed at reducing or eliminating gaps in health care coverage, and the Association continues to advocate for beneficiary protections by opposing the use of copay accumulator programs.  

On January 27, 2023, the Food and Drug Administration (FDA) approved elacestrant (Orserdu, Stemline Therapeutics, Inc.) for postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.

the Association for Clinical Oncology (ASCO), along with more than 100 other provider organizations, sent a letter to Members of Congress urging them to preserve access to high-quality care for beneficiaries by reforming the Medicare payment system. The letter urges Congress to hold hearings and work with stakeholders, such as ASCO, this year to identify long-term payment solutions.